Scarica l'app Stockscreener
1.74
2.96%
0.05
Pre-mercato:
1.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.69
Aprire:
$1.65
Volume 24 ore:
4.02M
Relative Volume:
0.61
Capitalizzazione di mercato:
$525.48M
Reddito:
$160.01M
Utile/perdita netta:
$-546.38M
Rapporto P/E:
-0.9482
EPS:
-1.835
Flusso di cassa netto:
$-118.92M
1 W Prestazione:
+20.00%
1M Prestazione:
+30.83%
6M Prestazione:
-12.12%
1 anno Prestazione:
+48.72%
Intervallo 1D:
$1.6401
$1.75
Intervallo di 1 settimana:
$1.47
$1.75
Portata 52W:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.74 | 510.38M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific Biosciences of California reveals unified approach to structural variant detection in cancer research - Traders Union
PacBio Stock (PACB) Opinions on Covaris FFPE Workflow Announcement - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Lowers Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences stock (US6932471010): Is long-read sequencing strong enough to unlock biotech up - AD HOC NEWS
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of "Hold" from Brokerages - MarketBeat
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing - Yahoo Finance
PacBio to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California compares leading long read sequencing technologies on accuracy and cost - Traders Union
May 7: PacBio investors get first-quarter results call and webcast - Stock Titan
Top Players and Competitive Dynamics in the Digital Genome Market - openPR.com
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples - Sahm
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance
PacBio, Covaris develop workflow for FFPE tissue sequencing By Investing.com - Investing.com Canada
Archived tumor samples gain long-read DNA workflow with 60% phasing - Stock Titan
Pacific Biosciences of California fosters connections and momentum at PacBioPRISM event - Traders Union
PACB Maintained by Barclays -- Price Target Lowered to $1.00 - GuruFocus
Barclays Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.00 - MarketBeat
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1 - Moomoo
Pacific Biosciences (PACB) Garnering Attention Amid Involvement in Trillion Gene Atlas Program - Insider Monkey
Pacific Biosciences of California introduces expanded long-read assay to streamline clinical workflows - Traders Union
Market Pulse: Can Pacific Biosciences of California Inc reach all time highs this yearQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - TradingView
How The PacBio (PACB) Story Is Shifting Between Long Term Potential And Near Term Risks - Yahoo Finance
Pacific Biosciences of California unveils step-by-step HiFi sequencing process leveraging Revio and Vega platforms - Traders Union
Director Christopher Gibson receives options and RSUs at Pacific Biosciences (PACB) - Stock Titan
Pacific Biosciences of California unveils SPRQ-Nx chemistry to streamline cancer testing workflows - Traders Union
Pacific Biosciences of California Inc (MEX:PACB) Stock Price, Trades & News - GuruFocus
Ontario-Based DNAstack Leads Sovereign AI for Genomics and Health with Goal of Making Canadians Healthier and Reducing Strain on our Healthcare System - marketscreener.com
PacBio HiFi WGS resolves hidden disease-linked structural variants in diverse populations - Traders Union
Fundamentals Check: Will Pacific Biosciences of California Inc outperform tech stocksWeekly Trend Summary & Reliable Entry Point Alerts - baoquankhu1.vn
MEX:PACB EV-to-OCF: -7.12 | Modestly Undervalued - GuruFocus
Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained - Bitget
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why - Yahoo Finance
Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.
Pacific Biosciences of California launches HiFi sequencing workshop at AACR26 for cancer genomics - Traders Union
Pacific Biosciences of California Inc (P09.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Pacific Biosciences of California traces DNA sequencing evolution from Sanger to HiFi platforms - Traders Union
Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes - Stock Titan
Pacific Biosciences of California Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView — Track All Markets
Pacific Biosciences of California expands HiFi WGS and targeted panels to detect hidden cancer variants - Traders Union
Pacific Biosciences of California, Inc. (PACB) latest stock news and headlines - Yahoo Finance Singapore
Trade Report: How does Pacific Biosciences of California Inc compare to its peersMarket Growth Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
[144] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing - Stock Titan
Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today - Bitget
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):